Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]

  • Awaiting development
  • GID-TA11670
  • Expected publication date: TBC

Suggested remit: To appraise the clinical and cost effectiveness of Savolitinib with durvalumab with chemotherapy within its marketing authorisation for treating unresectable locally advanced or metastatic MET-driven papillary renal cell
carcinoma